Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
Attralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field
The company also expanded the Board of Directors with the appointment of
“We are pleased to welcome
In leadership roles at publicly traded and global biopharmaceutical companies, Timney has successfully managed companies through stages of growth and transition, launched numerous breakthrough medicines, and led high-value strategic transactions. Most recently, Timney served as CEO and Board member of The Medicines Company where he led the company through late-stage clinical development and maximized the potential for inclisiran, a first-in-class siRNA cholesterol-lowering therapy. These actions increased shareholder return more than three-fold within one year and culminated in the company’s acquisition by Novartis. Previously, he held senior roles in biopharmaceutical companies that include Merck & Co.,
New Board Member
Rahul Kakkar, MD, Independent Board Director: Dr. Kakkaris a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience, spanning founding and building biotechnology companies, as well as working as a practicing physician. Most recently, he was Chief Executive Officer at Pandion Therapeutics, a company developing innovative modular therapeutics autoimmune and inflammatory diseases, which he led to reach the stage as a clinical-stage company and successfully completed an initial public offering prior to Pandion’s acquisition by Merck for $1.9 billion. Prior to joining Pandion, he served as an executive at Corvidia Therapeuticswhere he was a founder, Chief Medical Officer and Chief Strategy Officer, guiding the company from seed stage through Series B and its lead asset through clinical proof of concept. Corvidia was acquired by Novo Nordisk for $2.1 billion. Corvidia was a “spin-out” from AstraZeneca, where Dr. Kakkarhad served as Director for Emerging Innovations, responsible for preclinical through Phase 2 clinical studies both for compounds within the AstraZeneca pipeline and in support of compound out-licensing efforts. He continues to practice medicine as Associate Physician at Brigham and Woman’s Hospital and is a Lecturer in Medicine at Harvard Medical School. Dr. Kakkaris dual-trained via the American Board of Internal Medicine Fast Trackprogram in molecular biology and clinical cardiology, and he is a fellow of the American College of Cardiology.
New Executive Leaders
Attralus has appointed these veteran biopharmaceutical leaders who bring deep clinical, manufacturing and business expertise to support the company’s growth and clinical advancement of its pipeline.
Gregory Bell, MD, Chief Medical Officer: Dr. Bellhas extensive expertise in the development of investigational therapies, having recently served as Vice President, Safety Risk Management of the Immunology, Infectious Disease and Ophthalmology portfolio at Genentech. Previously, he was Senior Vice President, Development and Chief Medical Officer at KAI Pharmaceuticalswhere he led the global development of Parsabiv® until Amgen acquired KAI in 2012. Earlier in his career, Bell served as Vice President of Clinical Development, Biometrics and Clinical Operations at Abgenix with responsibilities across all clinical programs including Vectibix®; at Merck, he contributed to several products that received regulatory approval including Vioxx®, Etoricoxib® and Cancidas®. Prior to joining Attralus, Greg was Senior Vice President of Development at Global Blood Therapeutics.
Glen Firestone, Chief Business Officer: Mr. Firestonehas a distinguished 25-year career as an executive leader and has utilized his deep strategic and commercial expertise to build businesses, launch breakthrough therapies, improve patients’ lives and create value. Firestone recently led a consulting business advising biotech companies on corporate growth strategies, commercialization, product development, market access, and business development. Previously, he served as a strategic advisor to Valo Healthand was Head of Commercialization at Tmunity Therapeutics. Earlier, Firestone spent 20 years as a commercial executive at Merck with responsibility for leading many global and U.S.franchises, including the cardiovascular business, launching innovative medicines, building blockbuster product portfolios, negotiating business development deals and building partnerships.
Krishna Gorti, MD, Head of Corporate Development: Dr. Gortihas a rich and diverse background including roles in corporate development and investor relations, as an investment analyst covering biotechnology companies, as a physician trained in otolaryngology and head and neck surgery, and as a clinical and translational researcher. In his previous tenure with The Medicines Company, he served as Senior Vice President of Investor Relations and played an integral role in value-building initiatives, as well as working in earlier roles in business development and strategy. Prior to roles with biopharmaceutical companies, Gorti was a biotechnology industry equity research analyst with leading financial institutions, including JP Morgan, Piper Jaffrayand Rodman & Renshaw.
Michael Klein, PhD, Head of Chemistry, Manufacturing and Controls (CMC): Dr. Kleinhas more than 30 years of experience in the biotechnology industry, having spent his career working in various aspects of CMC development of therapeutic proteins, including monoclonal antibodies, Fc fusions, bispecific and multifunctional therapeutics. Most recently, Klein served as Vice President of Analytical Developmentat Nektar Therapeutics and was a member of the leadership team of the company’s Product Development and Manufacturing group. Previously, he was CMC scientific leader at Agenus, Atara Bio, Xencor, Protein Design Labsand Amgen.
About Systemic Amyloidosis
Systemic amyloidosis encompasses a diverse group of rare diseases that occur due to accumulation of toxic amyloid fibrils in tissues and organs, which is triggered by aberrant protein misfolding. These diseases are progressive, debilitating and often fatal. Systemic amyloidosis is significantly underdiagnosed due to low awareness, lack of specific symptoms, and no current disease-specific diagnostics. The two most common forms of systemic amyloidosis are transthyretin amyloidosis (ATTR) and amyloid light-chain (AL) amyloidosis.
Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. The company’s proprietary pan-amyloid removal (PAR) therapeutic product candidates are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis. Attralus was founded by scientific experts in the field of amyloidosis and is headquartered in
The Yates Network
Source: Attralus Therapeutics